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808Objective: The downregulation of human leukocyte antigen class I (HLA-I) has been proposed to contribute to
the immune evasion of cancer cells in some cancers. Meanwhile, transcriptional silencing by means of promoter
methylation is now believed to be an important mechanism of carcinogenesis. The aim of this study was (1) to
examine the expression of HLA-I antigen and the antigen-processing machinery components in patients with
esophageal squamous cell carcinoma lesions and (2) to detect the methylation pattern of the HLA-I gene in pa-
tients with esophageal squamous cell carcinoma and assess its association with histopathological characteristics.
Methods: A total of 87 formalin-fixed and paraffin-embedded esophageal squamous cell carcinoma lesions were
collected. HLA-I and antigen-processing machinery component expression was investigated by means of immu-
nohistochemistry with anti–HLA-I monoclonal antibody, and methylation changes in the promoter region of
HLA-1 genes were determined by using methylation-specific polymerase chain reaction.
Results: HLA-I, transporter associated with antigen processing 1, and low molecular weight protein were lost or
downregulated in 67%, 29.8%, and 47.0% of the esophageal squamous cell carcinoma lesions, respectively. The
positive rates of gene promoter hypermethylation of HLA-I was 70.1% (61/87) in tumor tissues compared with
3.6% in normal tissue (P<.01). Also, the higher methylation rates and the HLA-I expression were significantly
associated with tumor grade, including lymph node metastasis (P< .05).
Conclusions: HLA-I promoter hypermethylation was associated with loss of HLA-I antigen, which frequently
occurred in primary tumors, especially in metastatic lymph node lesions, and was associated with patients’
prognoses. (J Thorac Cardiovasc Surg 2011;141:808-14)Esophageal squamous cell carcinoma (ESCC) is a very
aggressive disease with a poor prognosis. Despite aggressive
treatment modalities, such as surgical tumor resectionwith ex-
tensive lymphadenectomy and chemoradiation therapy, only
20% to 36% of patients survive at 5 years.1 In recent years,
immunotherapy, such as the use of antitumor T cells or anti-
bodies induced by cancer vaccination, has become an attrac-
tive option for the revival of the role of immune surveillance
in the control of tumor growth.2 It is well known that human
leukocyte antigen class I (HLA-I) molecules are critical for
the presentation of antigen peptides, including those derived
from tumor cells, to cytotoxic T lymphocytes, and the down-
regulation of HLA-I on the tumor allows it to evade cytotoxic
T lymphocyte–mediated antitumor immunity, leading to vari-
ant cancer cells that arise from the parent tumor during tumor
progression at both primary and metastatic sites.3 Loss of
HLA-I antigen expression can occur at the genetic, transcrip-oracic Surgery, Second Hospital of Shandong University, Jinan, China.
res: Authors have nothing to disclose with regard to commercial support.
d for publication Jan 31, 2010; revisions received April 26, 2010; accepted for
ation April 30, 2010.
for reprints: Zhao Xiaogang, MD, Thoracic Surgery, Second Hospital of
ong University, 247 Beiyuan St, Jinan, Shandong 250033, China (E-mail:
lin2002@163.com).
23/$36.00
ht  2011 Published by Elsevier Inc. on behalf of The American Association
acic Surgery
016/j.jtcvs.2010.04.031
The Journal of Thoracic and Cardiovascular Surgtional, and posttranscriptional levels. DNAmethylation, espe-
cially 50 CpG methylation, is an important mechanism in
silencing the expression of genes.4,5 DNA methylation can
directly interfere with the basal transcriptional machinery by
altering the DNA secondary structure, especially the major
groove conformation. DNA methylation can also induce
chromosomal remodeling through histone deacetylation,
resulting in transcriptional repression. These events suggest
that DNA hypermethylation should be an important role in
the downregulation of HLA-I genes in patients with ESCC.
To our knowledge, there have been few reports describing
HLA-I expression in patients with ESCC and few describing
its mechanism, especially DNA methylation. Thus in this
study we investigated HLA-I expression in primary and meta-
static lesions in patients with ESCC using immunohistochem-
istry. Second, we investigated the methylation changes in the
promoter region ofHLA-I by usingmethylation-specific poly-
merase chain reaction (PCR). Furthermore, we evaluated the
correlation betweenmethylationofHLA-I and the clinicopath-
ological status or prognosis of patients with ESCC.MATERIALS AND METHODS
ESCC Specimen Preparation and DNA Extraction
Eighty-seven primary ESCC specimens containing neighboring epithe-
lial tissue were collected at the Second Hospital of Shandong University
in Jinan (Table 1). The samples were frozen in liquid nitrogen within 1
hour after surgical resection and were stored in liquid nitrogen on dry iceery c March 2011
TABLE 1. Characteristics of patients with ESCC
Characteristics Category No. (%)
Sex Male 61 (70.1)
Female 26 (29.9)
Age (y) 60 54 (62.1)
<60 33 (37.9)
Tumor differentiation Well 32 (36.8)
Moderate 19 (21.8)
Poor 36 (41.4)
Depth of invasion T1–T2 34 (39.1)
T3–T4 53 (60.9)
Tumor size (cm) 5 39 (44.8)
<5 48 (55.2)
Lymph node status Negative 52 (59.8)
Positive 35 (40.2)
Stage Low (I and II) 33 (37.9)
High (III and IV) 54 (62.1)
ESCC, Esophageal squamous cell carcinoma.
Abbreviations and Acronyms
APM ¼ antigen-processing machinery
ESCC ¼ esophageal squamous cell carcinoma
HLA-I ¼ human leukocyte antigen class I
LMP2 ¼ low molecular weight protein 2
PCR ¼ polymerase chain reaction
TAP1 ¼ transporter associated with antigen
processing 1
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Sat80C until use. For each specimen, 2 pieces of tissue, one from the tumor
mass, were dissected and embedded with tissue freezing medium (optimal
cutting temperature compound). Ten-micrometer-thick serial sections
were cryosected and used for DNA extraction. The presence of tumor or
normal tissue in the samples was confirmed histopathologically on slides
stained with hematoxylin and eosin. Cancerous lesions were microdissected
with a laser-capture microdissection system for the genetic assay. About 500
cells were dissected for each lesion. DNA was extracted with a Qiagen Tis-
sue Kit, according to themanufacturer’s procedures. The DNAwas stored in
aliquots at20C until use. None of the patients received radiotherapy, che-
motherapy, or other medical interventions before the study. This study was
approved by the Ethics Committee of the Shandong University, and written
informed consent was obtained from all subjects.
Immunohistochemical Staining
Immunohistochemical staining was performed with the PV6000 IHC
Kit. Briefly, sections were cut at 5 mm from the tissue microarray blocks.
After being dewaxed in xylene and rehydrated in alcohol and distilled water,
antigen was retrieved by means of microwave oven heating (10 minutes) at
middle power in 0.01 mol/L sodium citrate buffer (pH 6.0). The sections
were then incubated with 3% hydrogen peroxide in absolute methanol at
room temperature for 10 minutes to block endogenous peroxidase activity.
After 3 rinses (each for 5 minutes) in phosphate-buffered saline, the sections
were incubated sequentially with murine anti-human HLA-I antibody
(1:100; Proteintech Group), a rabbit anti-human transporter associated
with antigen processing 1 (TAP1) antibody (1:100, Proteintech Group),
and a murine anti-human low molecular weight protein 2 (LMP2) antibody
(1:100; Proteintech Group) diluted in phosphate-buffered saline overnight at
48C with 150 mL of polymerized horseradish peroxidase–anti-mouse/rab-
bit IgG for 30 minutes at room temperature. The reaction products were vi-
sualized with diaminobenzidine (Peking Zhongshan), and slides were
counterstained with hematoxylin, dehydrated, and evaluated under light mi-
croscope. Negative controls were done by omitting primary antibodies. For
the evaluation of HLA-I expression, 2 independent observers assessed
HLA-I positivity, without previous knowledge of clinicopathological data.
A consensus number was reached for each tumor sample between the 2
investigators. Normal lymphocytes and vessel endothelia were used in each
specimen as internal controls. Tumor specimens were scored as positive,
heterogeneous, or negative when the percentage of stained tumor cells in
an entire lesion was greater than 75%, 25% to 75%, and less than 25%,
respectively, according to the criteria established by the HLA and cancer
component of the 12th International Histocompatibility Workshop.6
Methylation-Specific PCR and Sequencing
The tumor and normal DNA were modified by means of a bisulfite reac-
tion with the procedure developed by Herman.7 For microdissected DNA,
1 mg of salmon spermDNAwas added as a carrier, followed by denaturation
with NaOH (final concentration, 0.2 mol/L). The DNA, in a volume of 50
mL, was incubated with 275 mL of modification buffer (10 mm of hydroqui-
none and 3 mol/L sodium disulfite, pH 5.0) for 16 hours at 50C. ModifiedThe Journal of Thoracic and CaDNA was purified with a Qiagen gel purification kit and then treated with
0.3 mol/L NaOH for 10 minutes at room temperature. The DNA was then
again purified with a Qiagen gel purification kit and eluted into 50 mL of
water. Methylation-specific and non–methylation-specific primers were de-
signed by using Primer3 (Table 2), which was developed and is maintained
by the Whitehead Institute/Massachusetts Institute of Technology Center of
Genome Research. Complete methylation was determined based on the
presence of methylation-specific and absence of non–methylation-specific
PCR products. Heterozygous methylation was scored when products
showed up in both methylation-specific and non–methylation-specific
PCR. High annealing temperatures were used to ensure the specificity of
both methylation-specific and non–methylation-specific PCR. About 20
to 50 ng of DNA was used in each PCR amplification. After 13 minutes
of heat activation, the reaction was incubated for 4 cycles of 2 minutes at
95C, 2 minutes at 65C, and then 2 minutes at 72C. The PCR reaction
then underwent 35 to 45 cycles of 10 seconds at 95C, 45 seconds at
62C, and 30 seconds at 72C. A 30-minute incubation at 72C was used
to finalize the PCR amplification. The products of PCR were purified by us-
ing shrimp alkaline phosphatase and exonuclease I: 1 U of shrimp alkaline
phosphatase and 6 U of exonuclease I were added into 8 mL of PCR
products. The mixtures were incubated at 37C for 60 minutes followed
by incubation at 70C for 10 minutes and sequenced (ABI3130XL).
Statistical Analysis
Statistical analysis was performed with SPSS 12.0 software. The c2 test
was used to compare the expression of HLA-I, LMP2, TAP1, and the
promoter methylation of HLA-I between primary tumors and lymph
node metastases of patients with ESCC and to assess their correlations be-
tween HLA-I antigen expression and the antigen-processing machinery
(APM) component expression and the expression of HLA-I, LMP2,
TAP1, and the hypermethylation of HLA promoter in ESCC lesions and
clinicopathological characteristics. All statistical tests were 2-sided. Uni-
variate analyses were conducted with the Cox proportional hazards model
to assess the correlation between survival time and multiple clinicopatho-
logical variables.RESULTS
Expression of HLA-I and APM Component in
Esophageal Lesions
All the antibodies were first tested on normal esophageal
tissues. As shown in Figure 1, esophageal surface epitheliumrdiovascular Surgery c Volume 141, Number 3 809
TABLE 2. Sequencing primers used for methylation analysis
Target locus Primer sequence(50/30) Product size (bp)
HLA_AF2 GGGTTTTTAGAGAAGTTAATTAGTGT 257
HLA_AR2 CCAAATCTAAATCAAAACCAAAACCC 197
HLA_BF2 GTGGGGATTTTAGAATTGGGAT 249
HLA_BR2 CCCCACTCCCCTAAATTTCAC 131
HLA_CF2 TGGGTGATTGGGGATTTTAGA 255
HLA_CR2 TCCACTCCCCTAAATTTCACTTC 151
HLA, Human leukocyte antigen.
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Sand stromal cells were homogeneously stained. Anti–HLA-I
showed strong staining of cell membranes, whereas anti-
TAP1 and anti-LMP2 primarily stained the intracellular
regions. Immunohistochemical staining of 87 primary
ESCC lesions (Figure 1) was done with the aforementioned
antibodies. Staining of lymphocytes was used as a reference
for the immunohistochemical staining in each tissue section.
Tumor lesions were found to have a highly variable expres-
sion profile ranging from a total loss to heterogeneous but de-
creased expression to normal expression. As shown in Table 2
and Figure 1, among the 3 proteins examined, HLA-I showed
the greatest reduction in expression (ie, negative in 34.5% and
downregulated in 23.0% of the lesions). TAP1 showed the
smallest reduction (ie, negative in 37.9% and downregulated
in 20.7% of the lesions). The expression levels of LMP2were
intermediate when compared with other proteins: LMP2 was
negative in 24.1% and downregulated in 29.9% of the lesions
(Table 3). Thus HLA class I antigen and APM components
were all downregulated in patients with ESCC.FIGURE 1. Representative staining patterns of primary esophageal squamous c
porter associated with antigen processing 1 (TAP1), and low molecular weight p
tense immunostaining for HLA-1, TAP1, and LMP2 was observed in most
immunostaining for HLA-1, TAP1, and LMP2 was observed in most esophagea
810 The Journal of Thoracic and Cardiovascular SurgAssociation of HLA Presentation With APM
Components
LMP2 participates in the proteosomal degradation of
antigens. TAP1 is responsible for the transport of the
antigen-derived peptide to the lumen of the endoplasmic
reticulum, where they are loaded on the newly synthesized
b2-microglobulin–associated HLA class I heavy chains
and transported through Golgi to the cell surface.8 Therefore
it is conceivable that abnormal expression of any of the APM
components might lead to defects in the expression of
HLA-I peptide complexes. To determine whether the ex-
pression of APM components affects the presentation of
HLA-I molecules, we carried out a correlation analysis. As
shown in Table 4 and Figure 2, the levels of all the examined
APM components were correlated to those of HLA-I mole-
cules, suggesting that the reduced expression of HLA-I in
tumor cells is partially attributed to the absence or reduction
of the components involved in the steps of antigen process-
ing and transport. In fact, a correlation between HLA-Iell carcinoma lesions with human leukocyte antigen class I (HLA-1), trans-
rotein 2 (LMP2) with antigen processing-specific monoclonal antibody. In-
normal esophageal and partly esophageal carcinoma epithelia. Negative
l carcinomas. (Original magnification 4003.)
ery c March 2011
TABLE 3. Expression of HLA-1 and APM components in ESCC cells
(positive)
IHC parameter
Tumor samples
(n ¼ 87)
Normal samples
(n ¼ 87)
HLA-1 37 (42.5%) 87 (100%)
TAP1 36 (41.4%) 86 (98.9%)
LMP2 40 (45.9%) 86 (98.9%)
HLA-1, Human leukocyte antigen class I; APM, antigen-processing machinery; ESCC,
esophageal squamous cell carcinoma; IHC, immunohistochemistry; TAP1, transporter
associated with antigen processing 1; LMP2, low molecular weight protein 2.
Qifeng et al Evolving Technology/Basic Scienceexpression and the levels of various APM components was
previously observed in patients with laryngeal squamous
cell carcinomas and ovarian cancers.9 These results suggest
that pathways leading to the loss or reduction of HLA-I
expression in cancer cells are probably shared among the
different types of cancer.FIGURE 2. Correlation of human leukocyte antigen (HLA) class I expres-
sion with antigen-processing machinery component expression in primary
esophageal squamous cell carcinoma lesions. The correlations between
the percentages of tumor cells stained by HLA-I–specific monoclonal
antibody and by transporter associated with antigen processing 1 (TAP1)–
specific monoclonal antibody or low molecular weight protein 2 (LMP2)–
specific monoclonal antibody in the lesions were analyzed with the
Spearman rank correlation coefficient (240 3 123 mm [192 3 192 DPI]).Association of HLA-I and APM Components With
Clinicopathological Characteristics
The association between the expression of HLA-I and
APM components and clinicopathological characteristics
was investigated in ESCC lesions. As can be seen in Table
2, the expression levels of HLA-I molecules are significantly
associated with tumor grade, the depth of tumor invasion,
the status of lymph nodes, and the clinical stage but are in-
dependent of age and tumor size. TAP1 expression is signif-
icantly associated with grade, stage, and lymph node status
of the tumor. LMP2 was significantly associated with tumor
stage and lymph node status of the tumor. Interestingly, the
expression level of LMP2 tended to be lower in patients aged
60 years or older. All the proteins examined were associated
with tumor stage and lymph node status of tumor. Tumor
stage and lymph node status of tumor were consistently as-
sociated with HLA-I molecules and the APM components
(Table 5).E
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SHypermethylation of 50 CpG Islands in HLA-A,
HLA-B, and HLA-C Gene Loci
The methylation status of the HLA-A, HLA-B, and
HLA-C CpG islands was investigated in 87 esophageal
cell carcinoma samples together with their adjacent normal
epithelial tissue by using methylation-specific PCR. We de-
tected hypermethylation of the HLA-A gene in 18 (20.6%)TABLE 4. Expression correlation of HLA-I with APM component
(P<.05)
TAP1 LMP2
HLA-1 Positive Negative Positive Negative
Positive 29 8 23 14
Negative 19 27 17 33
HLA-1, Human leukocyte antigen; APM, antigen-processing machinery; TAP1, trans-
porter associated with antigen processing 1; LMP2, low molecular weight protein 2.
The Journal of Thoracic and Cacases, of HLA-B in 23 (26.4%) cases, and of HLA-C in 27
(31%) cases. These were demonstrated by the presence of
products in both methylation-specific PCR and non–methyl-
ation-specific PCR (Figure 3). CpG islands in all 3 HLA
class I genes were concurrently methylated in 16 (18.4%)
of the 87 samples. Another 15 samples harbored methylation
in CpG islands of both the HLA-B and HLA-C genes.
HLA-A alone was methylated in 9 tumor samples, HLA-B
alone was methylated in 11 tumor samples, and HLA-C
alone was methylated in 10 samples. No methylation-
specific and only non–methylation-specific PCR signals
were detected for all of the 87 normal samples. To verify
the specificity of the PCR reaction, all of the products
from HLA-B methylation-specific PCR were cloned and
sequenced.rdiovascular Surgery c Volume 141, Number 3 811
TABLE 5. Correlation of HLA-I, TAP, LMP, and promoter methylation of HLA-I with clinicopathological characteristics in patients with ESCC
HLA-I TAP1 LMP2
Promoter methylation
of HLA
Characteristic þ ±  P value þ ±  P value þ ±  P value þþ* þ*  P value
Sex
Male 26 14 21 .908 23 12 26 .725 31 16 14 .203 22 20 19 .425
Female 11 6 9 13 6 7 9 10 7 9 10 7
Age (y)
60 24 10 20 .001 21 10 23 .424 29 16 9 .174 17 18 20 .071
<60 13 10 10 15 8 10 11 10 12 14 12 6
Tumor differentiation
Well 13 10 9 .05 15 8 9 .306 13 11 8 .05 10 13 9 .05
Moderate 9 4 6 7 2 10 8 6 5 7 6 6
Poor 15 6 15 14 8 14 19 9 8 14 11 11
Depth of invasion
T1–T2 20 9 5 .047 16 6 12 .818 15 11 8 .206 11 5 18 .007
T3–T4 17 11 25 20 12 21 25 15 13 20 25 8
Tumor size
5 cm 18 6 15 .284 12 5 20 .096 18 9 12 .196 21 17 6 .021
<5 cm 19 14 15 24 13 13 22 17 9 10 13 25
Lymph node status
Positive 15 6 14 .002 11 8 16 .188 17 10 8 .013 17 13 5 .002
Negative 22 14 16 25 10 17 23 16 13 14 17 21
Stage
I–II 17 10 6 .029 18 7 8 .282 17 9 8 .034 12 9 12 .011
III–IV 20 10 24 18 11 25 23 17 13 19 21 14
HLA-I, Human leukocyte antigen class I; TAP, transporter associated with antigen processing; LMP, low molecular weight protein; ESCC, esophageal squamous cell carcinoma;þ,
positive; , downregulation;, negative;þþ*, HLA-A, HLA-B, HLA-C, or 2 of them;þ*, HLA-A, HLA-B, or HLA-C.
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SAssociation of Hypermethylation of Promoter of
HLA-I With HLA Presentation and
Clinicopathological Characteristics
The association between the hypermethylation of the pro-
moter of HLA-I and clinicopathological characteristics was
investigated in ESCC lesions. As can be seen in Table 4, the
methylated levels of 50 CpG islands in HLA are significantly
associated with tumor grade, the depth of tumor invasion,
the status of lymph nodes, and the clinical stage but are
independent of age and tumor size, as shown in the HLA-IFIGURE 3. Methylation analysis of the promoter of the human leukocyte antig
(Y representing the T/C SNP). The different-colored curve represent the 4 base
812 The Journal of Thoracic and Cardiovascular Surgand APM component expression (Table 5). Also, to further
assess whether the hypermethylation of HLA-I promoter in
the primary tumor represented a prognostic parameter in pa-
tients with ESCC, we used the Cox proportional hazards
model and made the survival curve (Figure 4). The covariate
parameters included several clinicopathological factors in
addition to DNA hypermethylation. On univariate analysis,
several factors, including hypermethylation of HLA-I,
showed a significantly higher hazard ratio for a poor
prognosis. Those indicated that the DNA of HLA-Ien class I gene by sequencing. The arrows depict the methylated CpG site
s: red, T; green, A; black, G; blue, Y/C.
ery c March 2011
FIGURE 4. Survival curve in patients with esophageal squamous cell car-
cinoma. The median survival time in strong expression was significantly
shorter than in absent expression in terms of DNA hypermethylation.
Qifeng et al Evolving Technology/Basic Science
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Shypermethylation in patients with ESCC was closely related
to a poor prognosis (Table 6).
DISCUSSION
The HLA-I antigens HLA-A, HLA-B, and HLA-C, which
form the class I major histocompatibility complex in human
subjects, take part in the recognition of virally infected,
grafted, or transformed cells by cytotoxic T cells.3 The
HLA genes are located on chromosome 6p21 and are ex-
pressed in most somatic tissues. Selective loss of expression
of these loci has frequently been observed in human tumors,
and this event is thought to help tumor cells escape immune
surveillance by T cells and natural killer cells.10,11 The
downregulation of HLA-I has been observed in kidney, pros-
tate, stomach, colon, and germ cell testicular cancers and has
been associated with tumor invasiveness and aggressive-
ness.10 In our study we found that HLA-I was downregulated
or even lost in 78.2% of primary ESCC lesions and was
downregulated in 87% of metastatic lymph nodes. This fre-
quency in primary ESCC lesions is comparable with frequen-
cies reported in previous studies.12,13 Those studies and our
results clearly show that there is a marked reduction in the
expression of HLA-I molecules in ESCC lesions, and in our
studies we showed that the reduction of HLA-I presentation
was significantly associated with metastasis, tumor grade,
and poor survival in patients with ESCC. This is also compa-
rable with results reported in previous studies.14TABLE 6. Univariate analysis of patients
Univariate analysis, ove
Variables Categories HR (95% C
Sex Male (vs female) 1.75 (0.85-3.5
Tumor size (cm) 5 (vs<5) 2.43 (1.18-5.2
Hypermethylation Positive (vs negative) 4.03 (1.87-8.6
Tumor differentiation Poorly (vs well and moderate) 2.74 (1.31-5.7
HR, Hazard ratio; 95% CI, 95% confidence interval.
The Journal of Thoracic and CaLoss of HLA-I antigen expression can occur at the genetic,
transcriptional, and posttranscriptional levels. DNA methyl-
ation, especially 50 CpG methylation, is an important
mechanism in silencing the expression of genes.15,16 DNA
methylation can directly interfere with the basal
transcriptional machinery by altering the DNA secondary
structure, especially the major groove conformation. DNA
methylation can also induce chromosomal remodeling
through histone deacetylation, resulting in transcriptional
repression. A group of methyl-CpG–binding proteins,
which preferentially bind to methylated CpG dinucleotides,
might interact with sin3A. Sin3A in turn interacts with
histone deacetylase17 and is thought to be involved in this
process.18,19 Abnormal DNA methylation has been found
in various genes, including the putative tumor suppressor
genes retinoblastoma and p16INK4A, leading to their
downregulation in tumors.20 Costello and colleagues21 con-
ducted a global examination of CpG methylation in a large
group of tumors and observed a tumor type–specific pattern.
CpG islands are small regions of DNA ranging from 0.5 to 4
or 5 kb in length where the GC content is greater than 60%
and the CpG/GpC ratio is greater than 0.6.16 Using these cri-
teria, we have conducted a search for well-preserved CpG is-
lands in genes that have been reported to be inactivated by
high CpG/GpC ratios, as well as a GC content of greater
than 60%. Hypermethylation of these genes has not been re-
ported in either tumor or spermatogenic cells inwhichHLA-I
genes were not expressed.22
CpG island hypermethylation has been suggested to be
one of the major mechanisms for inactivation of genes that
inhibit tumor progression and infiltration.16 Each of the
3 HLA-I genes contains a well-preserved CpG island in its
50 region. Methylation-specific primers were designed to
amplify the region within or close to the promoters where
methylation has the greatest effect on transcription. Hyper-
methylation of each of the 3 loci was observed in some pa-
tients with ESCC, and methylation of HLA-B was
confirmed by means of sequencing. The HLA-B locus was
the most frequently hypermethylated, which is consistent
with the observation that in human tumors downregulation
of HLA class I expression was B locus specific.23 In this
study we analyzed the association between the expression
of HLA-I with the hypermethylation of its promoters and
concluded that they have an inverse correlation. Inrall survival Multivariate analysis, overall survival
I) P value HR (95% CI) P value
9) .13
1) .02 1.79 (0.71-4.53) .19
9) <.01 3.41 (1.42-8.33) .01
5) <.01 1.47 (0.57-3.81) .39
rdiovascular Surgery c Volume 141, Number 3 813
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Sesophageal epithelial tissue about 67% of promoters of
HLA-I have been detected methylated; meanwhile, the ex-
pression of HLA-I antigen was downregulated synchro-
nously. Furthermore, the methylation of HLA-I increases
with disease progression, with markedly less frequency in
primary lesions than in lymph node metastasis, and it was
significantly associated with tumor grade. Therefore we con-
clude that DNA hypermethylation is a mechanism for loss of
expression of the HLA-I genes in human ESCC. Activation
of HLA-I antigen expression has been proposed as a thera-
peutic approach for ESCC.24 Reactivation of tumor suppres-
sor genes through inhibition of DNA methylation has been
tested so as to inhibit cancer development.25 In fact, it has
been reported that the demethylating agents 5-azacytidine
and 5-aza–20-deoxycytidine can restore the normal demethy-
lated state of several types of tumor suppressor genes and in-
crease their expression in various cancers, including
esophageal cancer, in vitro and in vivo.26-28 Methylation
of genes in tumor cells could provide a tumor-specific target
for new therapies.29,30 However, to date, a clinical trial on
demethylating agents in esophageal cancer is unavailable.
Although it is too early to have any expectation about the
effect of these drugs on esophageal cancer, this is a very
promising concept and needs to be tested in clinical trials.
These approaches need to be studied further.
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